Department of Orthopaedic Surgery, Rothman Orthopaedic Institute, Thomas Jefferson University Hospitals, Philadelphia, PA, USA.
Department of Orthopaedic Surgery, Rothman Orthopaedic Institute, Thomas Jefferson University Hospitals, Philadelphia, PA, USA.
J Shoulder Elbow Surg. 2022 Jun;31(6S):S103-S109. doi: 10.1016/j.jse.2021.12.016. Epub 2022 Jan 19.
In cases of severe osteoarthritis, posterior glenoid wear leads to acquired retroversion of the glenoid. Surgical treatment of glenoids with acquired retroversion and posterior humeral subluxation with anatomic total shoulder arthroplasty (aTSA) is controversial. The purpose of this study was to determine mid- to long-term outcomes and reoperation rates of augmented and nonaugmented aTSA for treatment of glenohumeral osteoarthritis with Walch B3 glenoid deformity.
This observational cohort study reviewed patients with a Walch B3 glenoid undergoing aTSA at a single institution between 2007 and 2014. Patients were contacted to complete updated patient-reported outcome measures at a minimum of 6 years postoperatively. Outcome measures collected included the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES) score and Single Alpha Numeric Evaluation (SANE) score. Secondary outcomes included any additional surgery on the operative shoulder, patient satisfaction, and willingness to undergo aTSA again.
Thirty-nine patients met inclusion criteria, and thirty-five (89.7%) were able to be contacted for final outcomes evaluation. Mean follow-up was 8.7 years (range 6-13) after surgery. Sixteen patients were treated with an augmented glenoid component, and 19 patients were treated with a standard glenoid component. Of those with standard components, all were partially corrected with asymmetric reaming. At final follow-up, there were no statistically significant differences between those with augmented and standard glenoid components for mean ASES score (93.3 vs. 85.7, P = .217), ASES pain score (47.2 vs. 41.6, P = .161), SANE score (87.8 vs. 86.0, P = .692), and percentage patient satisfaction (95.6% vs. 96.8%, P = .735), forward elevation (148° vs. 149°, P = .852), or external rotation (36° vs. 39°, P = .202). No patient in either group had undergone revision surgery of the operative shoulder over the study period and all patients stated that they would undergo the same surgery again.
Both augmented and standard aTSA can provide satisfactory and sustained improvements in patient-reported outcomes in patients with acquired glenoid retroversion due to glenohumeral osteoarthritis. Despite a trend toward alternative treatment options, anatomic shoulder arthroplasty should remain a surgical consideration even in the setting of a Walch B3 glenoid deformity.
在严重骨关节炎的情况下,后肩胛盂磨损会导致肩胛盂发生后天性后旋。采用解剖型全肩关节置换术(aTSA)治疗伴有后天性后旋和肱骨头后脱位的肩胛盂存在争议。本研究的目的是确定采用增强型和非增强型 aTSA 治疗伴有 Walch B3 肩胛盂畸形的肩肱关节炎的中期至长期疗效和再手术率。
本观察性队列研究回顾了 2007 年至 2014 年期间在一家机构接受 aTSA 治疗的患有 Walch B3 肩胛盂的患者。至少在术后 6 年对患者进行了联系,以完成更新的患者报告的结果测量。收集的结果测量包括美国肩肘外科医师协会(American Shoulder and Elbow Surgeons)标准肩部评估表(ASES)评分和单一 Alpha 数值评估(Single Alpha Numeric Evaluation,SANE)评分。次要结果包括对手术肩部进行的任何其他手术、患者满意度以及是否愿意再次接受 aTSA。
39 名患者符合纳入标准,其中 35 名(89.7%)能够接受最终结果评估。术后平均随访时间为 8.7 年(6-13 年)。16 名患者接受了增强型肩胛盂组件治疗,19 名患者接受了标准肩胛盂组件治疗。在接受标准组件的患者中,所有患者均采用非对称扩孔进行部分矫正。在最终随访时,增强型和标准型肩胛盂组件在平均 ASES 评分(93.3 与 85.7,P=0.217)、ASES 疼痛评分(47.2 与 41.6,P=0.161)、SANE 评分(87.8 与 86.0,P=0.692)和患者满意度百分比(95.6%与 96.8%,P=0.735)、前屈活动度(148°与 149°,P=0.852)或外旋活动度(36°与 39°,P=0.202)方面均无统计学显著差异。在研究期间,两组均无患者对手术肩部进行了翻修手术,所有患者均表示愿意再次接受相同的手术。
对于因肩肱关节炎导致的后天性肩胛盂后旋患者,增强型和标准型 aTSA 均可提供令人满意且持续的患者报告结果改善。尽管有替代治疗选择的趋势,但解剖型肩关节置换术仍然应作为一种手术选择,即使在伴有 Walch B3 肩胛盂畸形的情况下也是如此。